Has Kevin Birusingh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $58,717 in general payments to Kevin Birusingh, MD across 224 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kevin Birusingh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kevin Birusingh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kevin Birusingh, MD

Urology · Des Moines, IANPI 1497915300

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $43,864 of the $58,717 with a category attached, or 74.7%. Teleflex LLC accounts for 90.0% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2022 at $44,784 and has fallen 98.7% since, to $574 in 2025. Among urology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$58,717in general payments, 2019–2025

Across 224 payments — averaging $262.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teleflex LLC$53K
Boston Scientific$877
Telix Pharmaceuticals$848
Neotract Inc.$505
Johnson & Johnson$494
AbbVie$296
plus $3K from 34 others

What the payments were for

Consulting fees$3,7636%
Speaking & faculty fees$43,86475%
Travel & lodging$3,7086%
Food & beverage$7,01812%
Education$3651%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teleflex LLC	83	$52,851
Boston Scientific	12	$877
Telix Pharmaceuticals	5	$848
Neotract Inc.	11	$505
Johnson & Johnson	13	$494
AbbVie(2 entities)	14	$296
Urogen Pharma, Inc.	7	$269
Arrow International, Inc.	1	$263
Astellas Pharma US Inc	8	$218
Dornier Medtech America, Inc	1	$195
Tolmar Pharmaceuticals, Inc.	3	$184
Medtronic	1	$160
Intuitive Surgical	1	$154
Procept Biorobotics Corporation	3	$148
Pfizer	7	$129
KARL Storz Endoscopy-america	3	$122
Novartis	4	$110
Dendreon Pharmaceuticals LLC	4	$103
Verity Pharmaceuticals Inc.	4	$78
Coloplast	5	$75
Olympus America Inc.	3	$74
Axonics, Inc.	3	$63
Amgen	3	$46
SRS Medical Systems, Inc.	1	$45
Travere Therapeutics, Inc.	4	$43
E.r. Squibb & Sons, L.L.C.	2	$35
Merck	2	$35
Cook Medical LLC	2	$34
Endo USA, Inc.	2	$33
Endo Pharmaceuticals Inc.	2	$33
Conmed Corporation	1	$33
Calyxo, Inc.	1	$25
Accord Healthcare, Inc.	1	$22
Bayer	1	$19
AstraZeneca	1	$18
Myovant Sciences Inc.	1	$17
BD	1	$17
C. R. Bard, Inc. & Subsidiaries	1	$16
Sumitomo Pharma America, Inc.	1	$16
Kowa Pharmaceuticals America, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,717 in reported general payments places this provider in the 95th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa →

Medicare billing

Part B allowed, 2024

$205,421

Medicare patients

345

Services billed

1,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	252	$2,132
Methenamine Hippurate	27	$2,018
Estradiol	14	$1,075
Finasteride	88	$578
Oxybutynin Chloride ErOxybutynin Chloride	34	$547
Methenamine Mandelate	11	$503
Levofloxacin	29	$86
Ciprofloxacin Hcl	13	$75
Cephalexin	13	$48

Paid to pharmacies, not to this prescriber.

Other urology in Des Moines

Richard GlowackiDes Moines$12K
Ryan SchulteDes Moines$3K
Vignesh PackiamIowa City$112K
Annah VollstedtIowa City$66K
Bradley EricksonIowa City$65K
Michael OdonnellIowa City$62K
Ryan DornbierClive$55K
Alexandria HertzIowa City$53K
John BuieIowa City$52K
Charles SchlaepferIowa City$51K

See the full list for Iowa →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →